Research Article Details
| Article ID: | A06003 |
| PMID: | 33040692 |
| Source: | Trop Doct |
| Title: | Effects of anthropometric and metabolic parameters on transaminase levels and liver stiffness in patients with non-alcohol fatty liver disease. |
| Abstract: | We aimed to investigate 214 patients further with non-alcoholic fatty liver disease (NAFLD) as judged by transient elastography. A body mass index of ≥25 was seen in 172 (80%) of the patients. F2-F4 fibrosis, as depicted by elastography, was present in 114 (53.2%). A Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) of ≥2 was seen in 178 (83.2%). Alanine aminotransferase was elevated in 116 (54%) and aspartate aminotransferase in 88 (41.1%). Liver steatosis was significantly associated with increasing alanine aminotransferase, insulin, HOMA-IR and cholesterol levels. Regression analysis showed cholesterol as a factor independently associated with the degree of liver steatosis. The independent variable related to increasing liver elasticity was steatosis. In conclusion, a significant number of our patients with NAFLD had steatohepatitis and F2-F4 fibrosis. |
| DOI: | 10.1177/0049475520962742 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D080 | Citrulline | Chemical drug | DB00155 | -- | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |